Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Claudio Napoli, Paola Bontempo, Vittorio Palmieri, Enrico Coscioni, Ciro Maiello, Francesco Donatelli & Giuditta Benincasa. (2021) Epigenetic Therapies for Heart Failure: Current Insights and Future Potential. Vascular Health and Risk Management 17, pages 247-254.
Read now
Read now
Sara Akbar, Nitin Kabra & Wilbert S Aronow. (2020) Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date. Therapeutics and Clinical Risk Management 16, pages 681-688.
Read now
Read now
Articles from other publishers (11)
K. A. Aitbaev, I. T. Murkamilov, V. V. Fomin, Zh. A. Murkamilova, I. O. Kudaibergenova & F. A. Yusupov. (2023) Effectiveness of apabetalone and some other indirect epigenetic-oriented drugs in the treatment of heart failure. Cardiovascular Therapy and Prevention 22:4, pages 3457.
Crossref
Crossref
Bertsetseg Dalaijargal, Le Mi, Zhuo Wu, Yao Yin, Hongyu Liang, Yan Qiu, Yi-Jia Yan, Hui Jin & Zhi-Long Chen. (2022) Synthesis and evaluation of new sartan derivatives. Medicinal Chemistry Research 31:6, pages 1003-1010.
Crossref
Crossref
Klaudia Kowalska, Justyna Walczak, Joanna Femlak, Ewelina Młynarska, Beata Franczyk & Jacek Rysz. (2021) Empagliflozin—A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals 15:1, pages 47.
Crossref
Crossref
Annayya R. Aroor, Srinivas Mummidi, Juan Carlos Lopez-Alvarenga, Nitin Das, Javad Habibi, Guanghong Jia, Guido Lastra, Bysani Chandrasekar & Vincent G. DeMarco. (2021) Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Lozhkina N.G. & Mukaramov I.. (2021) ACUTE AND CHRONIC HEART FAILURE AFTER MYOCARDIAL INFARCTION: CLINICAL AND FUNCTIONAL MARKERS. "Medical & pharmaceutical journal "Pulse", pages 83-90.
Crossref
Crossref
Daisuke Usuda, Toshihiro Higashikawa, Yuta Hotchi, Kenki Usami, Shintaro Shimozawa, Shungo Tokunaga, Ippei Osugi, Risa Katou, Sakurako Ito, Toshihiko Yoshizawa, Suguru Asako, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Jiro Oba, Tomohisa Nomura & Manabu Sugita. (2021) Angiotensin receptor blocker neprilysin inhibitors. World Journal of Cardiology 13:8, pages 326-340.
Crossref
Crossref
Daisuke Usuda, Toshihiro Higashikawa, Yuta Hotchi, Kenki Usami, Shintaro Shimozawa, Shungo Tokunaga, Ippei Osugi, Risa Katou, Sakurako Ito, Toshihiko Yoshizawa, Suguru Asako, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Jiro Oba, Tomohisa Nomura & Manabu Sugita. (2021) Angiotensin receptor blocker neprilysin inhibitors. World Journal of Cardiology 13:8, pages 325-339.
Crossref
Crossref
Alexander E Berezin & Alexander A Berezin. (2021) Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium–glucose co-transporter 2 inhibitors?. Future Cardiology 17:3, pages 497-506.
Crossref
Crossref
Imran Khan. (2020) A review of the Surgical Treatment for Ischemic Heart Failure trial. Asian Cardiovascular and Thoracic Annals 28:9, pages 633-637.
Crossref
Crossref
Alaa Alnefaie & Sarah Albogami. (2020) Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. Saudi Pharmaceutical Journal 28:11, pages 1333-1352.
Crossref
Crossref
V. S. Nikiforov. (2020) Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure. Meditsinskiy sovet = Medical Council:14, pages 34-39.
Crossref
Crossref